MARTINSRIED, Germany (Thomson Financial) - Evotec AG said it plans to
complete the acquisition of US peer Renovis Inc, initially announced Sept 19, at
the beginning of next year.
The German biotech company also said it has completed the sale of its
chemical development business to US-based Aptuit Inc for 31.5 bln stg, also
first announced in September.
Evotec in September said it was acquiring Renovis for about 151.8 mln usd
in shares to focus on treatments of neurological and inflammatory diseases and
that the combined company will apply for a Nasdaq listing.
ludwig.burger@thomson.com
lb/slm
COPYRIGHT
Copyright Thomson Financial News Limited 2007. All rights reserved.
The copying, republication or redistribution of Thomson Financial News Content,
including by framing or similar means, is expressly prohibited without the prior
written consent of Thomson Financial News.
|